Business Context and Reporting Period
Company: BioRestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2021
Reporting Period: The filing reports on a corporate action effective as of the opening of business on October 27, 2021.
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-4,000 reverse split of the Company's issued and outstanding common stock.
- Effective Date: The reverse split became effective on October 27, 2021.
- Regulatory Filing: A Certificate of Amendment was filed with the Secretary of State of the State of Delaware to effect the split.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. It references a press release issued on October 26, 2021, announcing the reverse split, but the text of the press release is not included in the provided content. No specific risks or contingencies are detailed in this document beyond the execution of the stock split.
Investor Verification Checklist
- Verify the post-split share count and the impact on the trading price of the common stock.
- Confirm the status of the Certificate of Amendment filed with the Delaware Secretary of State.
- Review the referenced press release (Exhibit 99.1) for additional details on the rationale for the reverse split.
- Check subsequent filings for any updates on the Company's financial condition or capitalization following the split.